Big Pharma: "[We] maintain an active dialogue with each of the candidates”
via The Intercept:
...
In terms of what we can expect after the election, anybody that thinks they can predict the nominations, much less the election right now, I would love to talk to them. But I think this is going to continue to be an issue, or it's going to continue to be on the radar screen because of demographics. And to some extent, as people get older, they are going to be more and more reliant on our medicines. I think we've got to continue to demonstrate that there's value in the medicines we bring. Yes, they can be expensive, but disease is a lot more expensive. And emphasize the fact that low-cost generics, which account for over four out of five prescriptions today, represent ultimately the legacy of these investment efforts on our part, and provide the American consumer with tremendous value. So I think you can assume the industry is going to continue to maintain an active dialogue with each of the candidates, and to work across party lines to make sure that the views that ultimately translate into policy -- and that's what we've really got to be focused on -- remain balanced and factual over time.
So I don't think there's -- while I think we are and should be concerned about the rhetoric, I think the facts of the underlying story remain very strong.
...
(emphasis mine)
https://beta.finance.yahoo.com/news/edited-transcript-lly-earnings-conference-025252746.html
From The Intercept:
Vijay Das, who is a healthcare policy advocate at the consumer group Public Citizen, says that the recent statements confirm that the pharmaceutical industrys pricing decisions are based upon the reach of their market and political power, not development costs or lengthy FDA approval process.
(emphasis mine)
Much more at:
https://theintercept.com/2016/02/02/goldman-sachs-pharma/
---------------------
Which candidate do you think would be more beholden to the industry? Which candidate do you know has no financial ties to the industry?
Which candidate will you choose in the primary process?